Trial abstract · §3
CJC-PH1-MULTIDOSE — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Pharmacodynamics of repeated weekly administration | Cumulative elevation of insulin-like growth factor 1 with repeated dosing. Development was not continued | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for CJC-1295 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported in phase 1 |
| Flushing | — | — | Reported |
| Fluid retention | — | — | Expected class effect of growth-hormone-axis stimulation |
| Glucose intolerance | — | — | Expected class effect; not systematically measured in the available human data |
| Arthralgia | — | — | Expected class effect |
Compound Evidence Institute · CEI-TR-0103/3 · https://compoundevidence.com/trials/cjc-ph1-multidose/results/ · retrieved 30 July 2026